文献速递慢性肾脏病血液净化与透析

预测2型糖尿病未诊断CKD患者eGFR下降模型的全球验证

Global Validation of a Model to Predict Reduced Estimated GFR in People With Type 2 Diabetes Without Diagnosis of CKD.
PubMed 文献 · Kidney Int Rep · 2024-04-04

本研究基于iCaReMe全球注册和DISCOVER研究数据,在14,180例无CKD 3-5期诊断的2型糖尿病患者中验证一个英国开发的低资源预测模型。结果显示英国模型全球应用会低估风险,而经区域截距重校准后的模型达到目标灵敏度80.5%(95%CI 78.8%-82.3%),阳性预测值相对筛查全部策略改善51.5%(95%CI 48.1%-55.1%),结论为区域调整模型全球性能 adequate,可用于风险分层和优先筛查。

要点

  • 英国开发的低资源模型全球外推会低估肾功能下降风险,需区域重校准。
  • 区域调整模型灵敏度达80.5%,PPV较筛查全部策略相对提升51.5%。
  • 该模型可帮助临床风险分层,尤其适用于中低收入国家的风险定制筛查。

核心结论

  • 经区域截距重校准的模型在全球2型糖尿病无CKD 3-5期诊断人群中性能 adequate,可辅助风险分层和优先筛查。

研究设计与样本

  • 回顾性观察研究,使用iCaReMe全球注册(NCT03549754)和DISCOVER研究(NCT02322762、NCT02226822)数据。
  • 共纳入14,180例2型糖尿病、无既往CKD 3-5期诊断且有血清肌酐或eGFR记录的患者,覆盖46个国家6个WHO区域。

主要发现

  • 英国原始模型全球应用时低估风险,被认为不适用。
  • 区域调整模型达到目标灵敏度80.5%(95%CI 78.8%-82.3%)。
  • 区域调整模型阳性预测值较筛查全部策略相对改善51.5%(95%CI 48.1%-55.1%)。

关键数值与推荐

  • eGFR<60 ml/min per 1.73 m2作为肾功能下降的标志。
  • 采用区域截距重校准调整区域变异。
  • 评估指标包括区分度和校准度。

临床怎么用

  • 可将区域调整模型嵌入实践,对2型糖尿病无CKD诊断患者进行风险分层和优先排序。
  • 风险定制筛查可提高效率,尤其在中低收入国家。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A minimal-resource model for predicting reduced kidney function among people with type 2 diabetes and no diagnosis of chronic kidney disease (CKD) stages 3 to 5 was previously developed in a UK population to pre-screen for undiagnosed CKD. This study aims to evaluate the performance of the model on a global population and assess its adequacy with and without regional adjustment. METHODS: A retrospective observational study was performed using data collected from the iCaReMe global registry (NCT03549754) and the DISCOVER study (NCT02322762 and NCT02226822). Patients were grouped by their World Health Organization classified region. An estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m2 was the marker of reduced kidney function. A regional-intercept recalibration was applied to adjust for regional variation. Discrimination and calibration were evaluated for the UK-developed and recalibrated models. RESULTS: A total of 14,180 patients (46 countries, 6 regions) were identified with type 2 diabetes, no previous diagnosis of CKD stages 3 to 5, and had a serum creatinine measurement or eGFR recorded. The UK model underestimated risk when applied globally and was deemed inadequate. The model with regional adjustment achieved the target sensitivity (80.5%; 95% confidence interval [CI]: 78.8%-82.3%) and demonstrated a relative improvement of 51.5% (95% CI: 48.1%-55.1%) in the positive predictive value (PPV), compared to a screen-all approach. CONCLUSION: The regional-adjusted model demonstrated adequate performance globally. Incorporating the model within practice could help clinicians to risk-stratify and prioritize patients at high risk. This could enable improved efficiency via risk-tailored screening, particularly in lower-middle-income countries (LMICs).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sammut-Powell C, Sisk R, Vazquez-Mendez E, et al. Global Validation of a Model to Predict Reduced Estimated GFR in People With Type 2 Diabetes Without Diagnosis of CKD. Kidney Int Rep. 2024. PMID: 39081746. doi:10.1016/j.ekir.2024.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。